evidence table

Berberine Blood Pressure Randomized Trial Evidence Table

Structured evidence table for Berberine Blood Pressure Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Berberine Blood Pressure Randomized TrialObjectives To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).2Lei L (2026)Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
Berberine Blood Pressure Randomized TrialBerberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42 [95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes.2Lei L (2026)Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
Berberine Blood Pressure Randomized TrialImportance Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.2Lei L (2026)Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
topicBerberine Blood Pressure Randomized Trial
claimObjectives To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
evidence level2
citationLei L (2026)
sourceBerberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
topicBerberine Blood Pressure Randomized Trial
claimBerberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42 [95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes.
evidence level2
citationLei L (2026)
sourceBerberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
topicBerberine Blood Pressure Randomized Trial
claimImportance Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.
evidence level2
citationLei L (2026)
sourceBerberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.

Learn next

Related evidence and supplement guides

SupplementBerberinePlant alkaloid with clinical evidence rivalling metformin for blood glucose control and lipid ma...GuideChokeberry Blood Pressure Randomized Trial: What the Evidence SaysChokeberry Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence...GuideHibiscus Blood Pressure Randomized Trial: What the Evidence SaysHibiscus Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence d...GuideGreen Coffee Blood Pressure Randomized Trial: What the Evidence SaysGreen Coffee Blood Pressure Randomized Trial has 2 source documents in the current Migaku eviden...GuideTocotrienols Blood Pressure Randomized Trial: What the Evidence SaysTocotrienols Blood Pressure Randomized Trial has 1 source documents in the current Migaku eviden...RankingBest Berberine Supplements 2026: Purity, Dose & BioavailabilityBerberine HCl is the standard form with the most clinical evidence. Dihydroberberine (DHB) offer...AnswerDoes Chokeberry Blood Pressure Randomized Trial work?Chokeberry Blood Pressure Randomized Trial has evidence relevant to strength of evidence and wha...AnswerIs Chokeberry Blood Pressure Randomized Trial safe?Chokeberry Blood Pressure Randomized Trial has evidence relevant to safety, limits, and clinicia...

Source documents

  1. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.